Publications

Publications

Comparison of low and intermediate source strengths for (125)I prostate brachytherapy implants.

By:
Contributors: Nawaid Usmani, MD, FRCPC, Sunita Ghosh, PhD
Brachytherapy. 2013 Sep-Oct;12(5):442-8. doi: 10.1016/j.brachy.2013.02.004. Epub 2013 May 23.

Abstract

PURPOSE:

To compare the implant quality and clinical outcomes for patients treated with low and intermediate strength (125)I seeds in prostate brachytherapy implants.

METHODS AND MATERIALS:

This retrospective review included 390 consecutive patients treated with prostate brachytherapy from 1999 to 2006. The first 142 patients were implanted with source strengths lower than 0.415U (0.327mCi), with the subsequent 248 patients implanted with source strengths higher than 0.493U (0.388mCi). Clinical, dosimetric, toxicity, and outcome data were compared between these two cohorts of patients.

RESULTS:

Despite having similar prostate volumes, fewer sources (median, 95 vs. 113; p<0.0001) and fewer needles (median, 23 vs. 29; p<0.0001) were implanted in the intermediate strength cohort. The postimplant dosimetry demonstrated better quality implants in patients treated with intermediate strength sources (median D90, 160.0Gy vs. 139.6Gy; p<0.0001), with greater dose inhomogeneity identified in the intermediate strength cohort of patients. A higher incidence of late rectal toxicity was identified in patients treated with intermediate strength sources despite lower rectal doses in this cohort. The biochemical relapse-free survival, prostate cancer survival, and overall survival were not significantly different between the two cohorts.

CONCLUSIONS:

The transition from low to intermediate strength sources has led to fewer resources being used and improved postoperative dosimetry. Although there were more rectal complications identified in the intermediate strength cohort of patients in this analysis, there were no other significantly worse clinical or biochemical outcomes for patients implanted with intermediate strength sources.

 

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Russ Greiner’s Team “PC LEARN”, tied for 1st in the Prostate Cancer DREAM Challenge

Competing with 50 teams from around the world in the Prostate Cancer DREAM Challenge, University of Alberta’s PC LEARN team tied for 1st in one of the 3 sub-challenges
to predict the survival and toxicity of Docetaxel treatment in patients with metastatic castrate resistant prostate cancer!

“The DREAM Challenge was an exciting opportunity for us to apply machine learning to real medical data and possibly to contribute to medical research.” said lead PI and APCaRI member Russ Greiner.

The primary benefit of this Challenge will be to establish new quantitative benchmarks for prognostic modeling in mCRPC, with a potential impact for clinical decision making and ultimately understanding the mechanism of disease progression. https://www.synapse.org/#!Synapse:syn2813558/wiki/70844

- Russ Greiner

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.